High Competition Among The Companies, New Product Launches By The Players is Enhancing The Growth of Allergy Immunotherapy Market at The CAGR of 10.8% by 2030

Market Research Future (MRFR) has published a cooked research report on the “Global Allergy Immunotherapy Market” that contains information from 2023 to 2030. The Global Allergy Immunotherapy Market is estimated to register a CAGR of 10.8% during the forecast period of 2023 to 2030.

Allergy Immunotherapy Market Highlights

The Global Allergy Immunotherapy Market is accounted to register a CAGR of 10.8% during the forecast period and is estimated to reach USD 4.9 Billion by 2030.

The Global Allergy Immunotherapy Market refers to the worldwide market for treatments aimed at alleviating and managing allergic conditions through immunotherapy. Allergy immunotherapy, also known as allergy shots or allergen-specific immunotherapy, is a medical intervention that involves exposing individuals to small amounts of allergens to desensitize their immune systems over time.

The market is influenced by the rising prevalence of allergic diseases worldwide. Factors such as environmental changes, increased urbanization, and lifestyle shifts have contributed to the growing burden of allergies.

Key Players:

MRFR recognizes the following companies as the key players in the Global Allergy Immunotherapy Market— ALK Abello, Allergy Therapeutics, Circassia, DVB Technologies, HAL Allergy Group, Merck KGaA Allergopharma, Aimmune therapeutics and Stallergenes Greer.

Segment Analysis

The Global Allergy Immunotherapy Market has been segmented based on type and treatment.

On the basis of type, the market is segmented into allergic rhinitis, allergic asthma, peanut allergy and cat allergy. Allergic rhinitis is the faster-growing segment. Consequently, it is anticipated that the market will experience profitable expansion due to the increasing disease burden caused by allergic disorders.

Based on treatment, the market has been segmented into sublingual immunotherapy, subcutaneous immunotherapy and specific immunotherapy. The sublingual immunotherapy is growing segment. This therapy can treat asthma, stinging insect hypersensitivity, and allergic rhinitis effectively. Moreover, SCIT has shown success in managing a variety of allergens. As a result, SCIT is more widely adopted than SLIT. For individuals who cannot receive allergy injections, SLIT is anticipated to become an essential option.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Allergy Immunotherapy Market Research Report

Regional Analysis

The Global Allergy Immunotherapy Market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Allergy Immunotherapy Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Allergy Immunotherapy Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Global Allergy Immunotherapy Market comprises of Middle East, Africa, and Latin America.

North America, including the United States and Canada, held a significant share of the global allergy immunotherapy market. The well-established healthcare infrastructure, growing awareness of allergy treatments, and the presence of major pharmaceutical companies contributed to the market's growth in this region.

Europe was also a prominent market for allergy immunotherapy. The region had a relatively high adoption rate of immunotherapy treatments, and the availability of advanced allergen extracts and immunotherapy formulations further boosted market growth.

The Asia-Pacific region showed promising growth potential in the allergy immunotherapy market. Countries like Japan, China, and South Korea had a rising prevalence of allergic diseases due to environmental changes and increased urbanization.

Furthermore, the rest of the world's Global Allergy Immunotherapy Market is divided into the Middle East, Africa, and Latin America. Latin America also witnessed increasing demand for allergy immunotherapy, driven by growing awareness of allergy treatments and improving healthcare infrastructure. Brazil, Mexico, and Argentina were among the leading markets in the region.

Key Findings of the Study

• North America, including the United States and Canada, held a significant share of the global allergy immunotherapy market. The well-established healthcare infrastructure, growing awareness of allergy treatments, and the presence of major pharmaceutical companies contributed to the market's growth in this region.


• Based on treatment, the market has been segmented into sublingual immunotherapy holding the largest market in 2022.


• ALK Abello, Allergy Therapeutics, Circassia, DVB Technologies, Aimmune therapeutics, HAL Allergy Group, Merck KGaA Allergopharma and Stallergenes Greer.